Heidi Karon, MD
Endocrinology, Diabetes & Metabolism · Laurel, MDNPI 1144361155
Payments from drug & device makers
Across 63 payments — averaging $46.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Lilly USA, LLC$162
- AbbVie$153
- Dexcom, Inc.$142
- Corcept Therapeutics$79
- Sanofi-aventis U.S. LLC$73
- plus $666 from 19 others
What the payments were for
- Speaking & faculty fees$1,60854%
- Food & beverage$1,35046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 5 | $1,684 |
| Lilly USA, LLC | 8 | $162 |
| AbbVie | 7 | $153 |
| Dexcom, Inc. | 6 | $142 |
| Corcept Therapeutics | 3 | $79 |
| Sanofi-aventis U.S. LLC | 3 | $73 |
| Abbott | 3 | $67 |
| Amneal Pharmaceuticals LLC | 4 | $65 |
| Novo Nordisk | 3 | $64 |
| Tandem Diabetes Care, Inc. | 1 | $64 |
| Ascendis Pharma Endocrinology Inc | 2 | $55 |
| Bayer | 2 | $46 |
| Johnson & Johnson | 3 | $45 |
| Almatica Pharma LLC | 2 | $42 |
| BETA Bionics, Inc. | 1 | $28 |
| Lifescan, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Globus Medical | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,608
How this compares
$2,958 in reported general payments places this provider in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 177 | $358,705 |
| JardianceEmpagliflozin | 131 | $186,143 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $81,478 |
| TrulicityDulaglutide | 41 | $81,475 |
| MounjaroTirzepatide | 52 | $73,160 |
| FarxigaDapagliflozin Propanediol | 31 | $52,952 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $40,492 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $29,700 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $22,567 |
| JanuviaSitagliptin Phosphate | 18 | $19,102 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $17,263 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $15,659 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,124 |
| SynthroidLevothyroxine Sodium | 133 | $11,979 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 78 | $10,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $64 | $358,705177 claims |
| Boehringer IngelheimJardiance | $21 | $186,143131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $162 | $154,63493 claims |
| AbbVieSynthroid, Armour Thyroid | $153 | $14,140156 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $65 | $5,164307 claims |
| IBSA Pharma Inc.Tirosint | $22 | $5,09413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Laurel
- Nicholas ArgentoLaurel$1.1M
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.